Podcast: Play in new window | Download (Duration: 28:25 — 26.8MB)
Subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | TuneIn | RSS | More
My Guest this week of October 7th is Dr. Timothy Boyd, PHD, who works at the Rocky Mountain Alzheimer’s Disease Center in Colorado. Dr. Boyd shared astonishing and hopeful findings of an exciting research trial, designed to end Alzheimer’s, this week on my show. Explaining their Leukine Trial, Boyd told my listeners that preliminary results on the first human trials of the drug “Leukine” as a treatment for Alzheimer’s have met with unexpected success. Dr. Boyd, who works with the team headed by renowned researcher Dr. Huntington Potter, shared the news with a detailing of their initial results. Essentially, the first safety trials for Leukine involved 32 people with the disease. 13 were injected with the drug itself. 19 others received a placebo, or, just plain salt water. The results were surprisingly positive. Compared to their starting place, the people who received Leukine actually improved in their cognition, as measured by the MMSE, which is the Mini Mental State Exam. And the people who received the salt water placebo stayed the same. So that means that at the end of treatment there was a big difference between the people who received Leukine and the people who received placebo. Further, the patients who did improve did so quickly. They were showing results in just a matter of three weeks, after only some 15 injections. “Alzheimer’s disease takes probably decades before it even starts to present the first signs of having any cognitive impairment,” said researcher Dr. Timothy Boyd. “So to improve cognition within only 15 days of an injection of a treatment–that is very astonishing.” And even more remarkable is that within that same period of time, the Leukine patients actually began to show some improvement in day to day activity, able to once again do things that the disease had taken from them. Listen to my interview to learn more!
